Impact of exercise training in combination with dapagliflozin on physical function in adults with type 2 diabetes mellitus: A randomised controlled trial
(Dapagliflozin, Exercise Training and physicAl function: the DETA trial)
Principle Investigator: Prof. Melanie Davies
Type 2 diabetes mellitus (T2DM), a disease characterised by high blood sugar levels, is also known to affect whole body health and fitness. As a result it can be thought of as a disease of accelerated ageing. This means that people with T2DM may find their physical health declines at an earlier age than someone without diabetes, making everyday activities harder. Being overweight and obese can make this even worse.
Several treatments for T2DM help with weight loss, with the potential to also improve overall physical health. Dapagliflozin is a type of medication called a sodium-glucose co-transporter 2 inhibitor (SGLT2i), which is widely used in routine clinical care. Dapagliflozin reduces blood sugar levels and also helps with weight loss.
However the extent to which dapagliflozin can also help improve overall physical health is not known.
This study will investigate whether dapagliflozin can be used to improve overall physical health, measured by how easy it is to undertake activities of daily living, and whether combining it with a programme of exercise can make the benefits even greater. The study will also look at the effect of dapagliflozin with and without exercise on blood sugar levels, other blood markers of health and the heart’s pumping ability and overall heath.
For more information about the DETA trial, please contact us:
Phone: 0116 258 8897